ArticlePoultry science2025
Comparative analysis of model antigen expression level driven by the microneme protein promoters in Eimeria tenella.
Article in Poultry science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An oral Eimeria-vectored vaccine induces protective immunity against chicken infectious anemia.NPJ vaccines · 2026Article
- Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coccidiosis is the most severe parasitic disease affecting the poultry industry, and live vaccines have played a pivotal role in its prevention and control, making them the most successful parasitic disease vaccines in commercial use. The components of live coccidiosis vaccines, which serve as vaccine vectors for presenting antigens from other pathogens, offer several advantages and provide a promising new option for disease control in modern poultry farming. Enhancing the expression of heterologous antigens within the complex components of Eimeria is a key strategy for optimizing coccidial vectors and improving immune efficacy. Since secreted antigens can stimulate strong immune responses in the host, we conducted a comparative analysis of the transcription levels of the microneme protein, the most important secretory organelle in apicomplexan parasites, across different stages of the life cycle. Three candidate genes with high transcription levels throughout the entire life cycle (excluding the unsporulated oocyst stage) were selected: ETH2_1343100, ETH2_0957500, and ETH2_1219600. We amplified the upstream (∼1500 bp) and downstream (∼1000 bp) regions of these genes to serve as promoters and regulatory sequences for the enhanced yellow fluorescent protein (EYFP) reporter gene expression cassette. This cassette was then incorporated into a dual-expression vector, fused with a selection marker consisting of a mutated prolyl-tRNA synthetase (PRS) gene and mCherry. After transfecting the plasmids into sporozoites and obtaining recombinant Eimeria strains with stable EYFP expression, we analyzed the fluorescence intensity of EYFP using laser confocal microscopy combined with fluorescence intensity analysis. Recombinant Eimeria driven by the histone 4 (EtHis4) promoter was used as a control. The results showed that the promoters of the three microneme protein genes regulated fluorescence expression levels approximately three times higher than the EtHis4 promoter, with the ETH2_1343100 promoter proving to be the most effective. These findings provide new regulatory sequence options for the genetic manipulation of Eimeria and the enhancement of foreign gene expression, accelerating its potential application as a vaccine vector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.